<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415051</url>
  </required_header>
  <id_info>
    <org_study_id>FY04-33, Log A-13698</org_study_id>
    <nct_id>NCT00415051</nct_id>
  </id_info>
  <brief_title>Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine</brief_title>
  <acronym>MP-12</acronym>
  <official_title>Safety and Immunogenicity of Live-Attenuated MP-12 Rift Valley Fever Vaccine in Humans, and Genetic Characterization of Virus Isolates Recovered From the Blood of Vaccinated Volunteers: A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to
      humans. The study will examine how well the vaccine (RVF MP-12) stimulates the body's immune
      response (which fights off infection) and if the vaccine is stable or if the virus used to
      make the vaccine changes into a different form once injected into the body. Twenty healthy
      volunteers (18-50 years old) will be vaccinated with a single dose of undiluted RVF MP-12,
      injected into a muscle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rift Valley Fever (RVF) is a mosquito-borne disease in Africa that affects both humans and
      animals. The disease poses a significant endemic disease threat, and the etiologic agent (RVF
      virus) possesses physical and biochemical characteristics that have resulted in its
      classification as a Category A Agent. Historically, this disease was confined to Africa. In
      September 2000, however, RVF appeared in the western part of the Kingdom of Saudi Arabia (843
      cases with 114 deaths) and in Yemen (1,087 suspected cases with 121 deaths). It is thought
      that Rift Valley fever was introduced into this new geographic area through importation of
      infected livestock from Djibouti. Mosquito transmission has been subsequently demonstrated in
      these areas, suggesting that the disease may have become permanently established. A safe and
      effective RVF vaccine capable of inducing protective immunity after a single injection is
      urgently needed. Currently, no drug is available that will alter the course of the disease in
      humans or animals, nor is any licensed vaccine for RVF approved for human use. This protocol
      is an open-label, Phase II study to assess the safety, immunogenicity and genetic stability
      of RVF MP-12 vaccine in humans. The objectives of this study are to collect safety and
      immunogenicity data for an intramuscular (IM) injection of live, attenuated, mutagenized RVF
      12th mutagenesis passage (MP-12) vaccine and characterize isolates of the Rift Valley fever
      (RVF) MP-12 vaccine recovered from blood of vaccinated volunteers using in vitro systems to
      evaluate genetic stability. A total of 20 volunteers will be recruited from among military
      and civilian persons at and around USAMRIID and from the general population in and around
      Frederick, Maryland, who expect to remain in the area for the duration of the study.
      Volunteers will be vaccinated with undiluted RVF MP-12 vaccine. Safety will be evaluated by
      recording the frequency and severity of clinical reactions to the vaccine, as well as by
      measuring complete blood counts and selected serum biochemistry (enzyme) values.
      Immunogenicity will be evaluated by measuring 80% plaque reduction neutralization (PRNT80)
      antibodies to RVF virus for periods up to 1 year following vaccination. Genetic stability of
      the vaccine will be evaluated by examining isolates recovered from blood of vaccinated
      volunteers by molecular sequencing techniques, and comparing these findings with those from
      the vaccine virus inoculum. Subjects will participate in the study for up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as Measured by the Number of Adverse Events</measure>
    <time_frame>up to 1 year</time_frame>
    <description>AE's will be assessed through study completion. Safety will be evaluated by recording the frequency of clinical reactions to the vaccine and by measuring complete blood counts and selected serum biochemistry (enzyme) values, rates of hospitalizations, and rates of lost duty/work time overall and by gender.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Response Assessed by Measuring Days to Peak Response for PRNT80 Antibodies to RVF Virus</measure>
    <time_frame>Days 0, 1, 2, 3, 7, 10, 14 and 28, Months 3, 6 and 12</time_frame>
    <description>Immune response will be assessed by measuring days to peak response for PRNT80 antibodies to RVF virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response Assessed by Measuring Days to Peak Response for (PRNT50) RVP MP-12 Vaccine</measure>
    <time_frame>Days 0, 1, 2, 3, 7, 10, 14 and 28, Months 3, 6 and 12</time_frame>
    <description>Immune response will be assessed by measuring days to peak response for PRNT50 antibodies to RVF virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic Stability - Characterize Viral Isolate (Plasma) Frequency</measure>
    <time_frame>Days 0-14</time_frame>
    <description>In vitro systems will be used to evaluate genetic stability (examining viremia levels in plasma by direct plaque assay techniques or by blind passage of plasma on Vero cells and sequencing the ribonucleic acid (RNA) and comparing these findings with those from the vaccine virus inoculum).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Rift Valley Fever</condition>
  <arm_group>
    <arm_group_label>Single Group Assignment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RVF MP-12</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RVF MP-12</intervention_name>
    <description>Administer 1 ml SQ</description>
    <arm_group_label>Single Group Assignment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 50 years old

          -  Free of chronic medical conditions requiring ongoing therapy and in general good
             health as determined by a physician investigator

          -  Have a current (within 30 days of scheduled blood donation for this study) complete
             blood (cell) count (CBC) to include a Hct and Hgb that show no evidence of anemia, and
             total white blood cell with differential platelet counts that are within normal range,
             as well as hepatic enzyme (AST, ALT, LDH) values that are within normal laboratory
             ranges

          -  Negative human immunodeficiency virus (HIV) antibody test within 3 months preceding
             vaccination

          -  No evidence of pre-existing liver disease or current infection with Hepatitis A, B, or
             C virus as determined by serology

          -  No evidence for pre-existing eye disease, as determined by fundoscopic/slit lamp
             examination by the study ophthalmologist other than refractory changes

          -  No evidence by history or serologic testing for previous infection with RVF virus or
             RVF vaccine

          -  Subjects must agree to refrain from intimate contact (sexual activity), or use barrier
             contraception (e.g., condoms), for the 2-week period following vaccination

          -  Females of child-bearing potential must have a negative serum pregnancy test on
             screening and the morning of vaccination prior to receipt of the vaccine and must
             agree to use a highly effective method of birth control during the first 3 months
             following receipt of the MP-12 vaccine. A highly effective method of birth control is
             defined as one with a failure rate of less than 1% per year. Acceptable birth control
             methods that meet this criterion include hormonal implants and injectables (Norplant,
             Dep-Provera, Lunelle, and Etonogestrel); combined oral contraceptives; the
             intrauterine devices (IUDs) Copper T (380-A) or Mirena (Levonorgestrel Intrauterine
             System); female sterilization (tubal ligation); sexual abstinence; or a vasectomized
             partner.

          -  Subjects must be medically cleared for participation by an investigator

          -  Subjects must expect to remain in the area for the duration of the study

          -  Volunteer must sign an approved informed consent

          -  Volunteer must be willing to return for all follow-up visits including a
             post-vaccination ophthalmologic visit

          -  Volunteer must be willing to refrain from excessive (more than individual's normal
             routine) exercise for a period of at least 2 weeks prior to and following vaccination

          -  Volunteer must be willing to abstain from drinking alcoholic beverages for a period of
             at least 2 weeks prior to and following vaccination. Volunteer must not be a &quot;weekend&quot;
             drinker or normally drink more than 2 drinks a day if male or 1 drink a day if female.

          -  Volunteer must agree to report any adverse event (AE) that may or may not be
             associated with administration of the test article during their participation in the
             study.

        Exclusion Criteria:

          -  History or evidence of liver disease/abnormality

          -  History of pre-existing thymic disease or thymic dysfunction (any cellular immune or
             antibody disorders)

          -  Be taking any medication, prescription or non-prescription (excluding dietary
             supplements), on a regular basis with the exception of contraceptive pills. This
             includes the regular use of statins, non-steroidal anti-inflammatory drugs (NSAIDs),
             immunosuppressive agents, antivirals, topical steroidal creams, and nasal sprays.
             Conditions requiring intermittent medications and other decisions regarding
             eligibility due to medication use will be deferred to physician investigators.

          -  Elevation above the upper limit of laboratory normal values in liver enzymes, or
             history of unexplained elevation in liver enzymes

          -  History or evidence of eye disease (excluding changes in refraction and strabismus)

          -  Abnormal clinical lab results indicating evidence of anemia, immunosuppression, or
             immune deficiency disease

          -  Have donated 1 unit (500 cc) or more of blood for any reason during the 2 months (56
             days) preceding administration of the vaccine (as assessed by query)

          -  Plan to donate blood within 1 year following receipt of the vaccine

          -  History or evidence of previous infection with RVF or vaccination against RVF

          -  Any known allergies to components of the vaccine: Human serum albumin (stabilizer),
             Sol-U-Pro, Neomycin (antibiotic), sorbitol, L-proline, L-arginine, monosodium
             glutamate (MSG), or Urea

          -  Administration of another vaccine within 4 weeks of RVF MP-12 vaccination

          -  &quot;Weekend&quot; drinkers, males who drink more than 2 drinks a day and females who drink
             more than 1 drink a day, will be excluded

          -  Individuals who plan to start a new exercise program within two weeks of vaccination
             (either two weeks prior to or two weeks following vaccination) will be excluded.
             Individuals who are already on a regular exercise program and who have normal
             transaminase levels will not be excluded but will be advised not to increase their
             level of activity for a period of one month (for two weeks prior to until two weeks
             after vaccination). Individuals who do not exercise regularly and who participate in
             this study will be advised not to embark on an exercise program for the same time
             period.

          -  Volunteers will be cautioned against salivary contact and contact with infants,
             children under the age of 8 years, adults over the age of 64 years, and anyone who is
             immunocompromised or in poor health. Volunteers who feel unable to comply with these
             restrictions will be excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Pittman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USAMRIID Medical Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US Army Medical Research Institute of Infectious Diseases</name>
      <address>
        <city>Fort Detrick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2006</study_first_submitted>
  <study_first_submitted_qc>December 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <results_first_submitted>December 6, 2016</results_first_submitted>
  <results_first_submitted_qc>December 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2017</results_first_posted>
  <disposition_first_submitted>June 8, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>June 8, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 7, 2015</disposition_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rift Valley Fever, vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Coccidioidomycosis</mesh_term>
    <mesh_term>Coccidiosis</mesh_term>
    <mesh_term>Rift Valley Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty subjects were planned; 31 were screened, 11 did not meet the inclusion/exclusion criteria, 20 satisfied inclusion/exclusion criteria, 20 were enrolled, 1 was excluded (received another vaccine within 30 days of intended MP-12 vaccination), and 19 received vaccine and completed the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Group Assignment</title>
          <description>RVF MP-12
RVF MP-12: Administer 1 ml SQ</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Group Assignment</title>
          <description>RVF MP-12
RVF MP-12: Administer 1 ml SQ</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="23" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety as Measured by the Number of Adverse Events</title>
        <description>AE's will be assessed through study completion. Safety will be evaluated by recording the frequency of clinical reactions to the vaccine and by measuring complete blood counts and selected serum biochemistry (enzyme) values, rates of hospitalizations, and rates of lost duty/work time overall and by gender.</description>
        <time_frame>up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group Assignment</title>
            <description>RVF MP-12
RVF MP-12: Administer 1 ml SQ</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Measured by the Number of Adverse Events</title>
          <description>AE's will be assessed through study completion. Safety will be evaluated by recording the frequency of clinical reactions to the vaccine and by measuring complete blood counts and selected serum biochemistry (enzyme) values, rates of hospitalizations, and rates of lost duty/work time overall and by gender.</description>
          <units>AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local AEs Related and Not Related to Study Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic AEs Related and Not Related to Study Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response Assessed by Measuring Days to Peak Response for PRNT80 Antibodies to RVF Virus</title>
        <description>Immune response will be assessed by measuring days to peak response for PRNT80 antibodies to RVF virus</description>
        <time_frame>Days 0, 1, 2, 3, 7, 10, 14 and 28, Months 3, 6 and 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group Assignment</title>
            <description>RVF MP-12
RVF MP-12: Administer 1 ml SQ</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response Assessed by Measuring Days to Peak Response for PRNT80 Antibodies to RVF Virus</title>
          <description>Immune response will be assessed by measuring days to peak response for PRNT80 antibodies to RVF virus</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days to peak PRNT80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" spread="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days to peak PRNT80 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response Assessed by Measuring Days to Peak Response for (PRNT50) RVP MP-12 Vaccine</title>
        <description>Immune response will be assessed by measuring days to peak response for PRNT50 antibodies to RVF virus</description>
        <time_frame>Days 0, 1, 2, 3, 7, 10, 14 and 28, Months 3, 6 and 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group Assignment</title>
            <description>RVF MP-12
RVF MP-12: Administer 1 ml SQ</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response Assessed by Measuring Days to Peak Response for (PRNT50) RVP MP-12 Vaccine</title>
          <description>Immune response will be assessed by measuring days to peak response for PRNT50 antibodies to RVF virus</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days to peak PRNT50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" spread="101.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days to peak PRNT50 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genetic Stability - Characterize Viral Isolate (Plasma) Frequency</title>
        <description>In vitro systems will be used to evaluate genetic stability (examining viremia levels in plasma by direct plaque assay techniques or by blind passage of plasma on Vero cells and sequencing the ribonucleic acid (RNA) and comparing these findings with those from the vaccine virus inoculum).</description>
        <time_frame>Days 0-14</time_frame>
        <population>1 subject was excluded for receiving another vaccination within 30 days of intended MP-12 vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Group Assignment</title>
            <description>RVF MP-12
RVF MP-12: Administer 1 ml SQ</description>
          </group>
        </group_list>
        <measure>
          <title>Genetic Stability - Characterize Viral Isolate (Plasma) Frequency</title>
          <description>In vitro systems will be used to evaluate genetic stability (examining viremia levels in plasma by direct plaque assay techniques or by blind passage of plasma on Vero cells and sequencing the ribonucleic acid (RNA) and comparing these findings with those from the vaccine virus inoculum).</description>
          <population>1 subject was excluded for receiving another vaccination within 30 days of intended MP-12 vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9 afterr vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12 afterr vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 13 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 13 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 after vaccination - Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 after vaccination - Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Within 30 days post vaccination, 119 AEs (22 local and 97 systemic) were reported. Between 31 days and 1 year post vaccination, 33 systemic AEs (no local AEs) were reported. A total of 152 AEs (22 local and 130 systemic) were reported during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Single Group Assignment</title>
          <description>RVF MP-12
RVF MP-12: Administer 1 ml SQ</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervial nodes slightly tender</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Increase in bleeding post venipuncture</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart palpitations</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Left eye itching</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Throat scratchy and sore</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis (OS)</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Shoulder injury</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Traumatic injury to L middle finger</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Muscle pain</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lower back discomfort</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Knee joint pain</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dental pain</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ankel pain</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Stiff neck</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Knee pain</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Muscle ache</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain (chest and back)</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain (lower back)</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain (shoulder)</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Shin splints</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Stiff neck</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eyelid twitching</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lightheaded</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Spacey</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eye twitching</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Migrane</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstrual cramps</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain (testicle)</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chest congestion</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cold</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tenderness (vaccine site)</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Redness (vaccine site)</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Clammy skin (hands)</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bruise</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Injection site warm</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Redness (phlebotomy site)</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cold sore</sub_title>
                <description>&lt; 30 Days Post Vaccination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Scar reconstruction ABD wall liposuction</sub_title>
                <description>31 days - 1 year post vaccine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>COL Phillip R. Pittman, MD, MPH</name_or_title>
      <organization>US Army Medical Research Institute of infectious Diseases (USAMRIID)</organization>
      <phone>301-619-4994</phone>
      <email>phillip.pitman@amedd.army.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

